Compare BANC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANC | BEAM |
|---|---|---|
| Founded | 1941 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | BANC | BEAM |
|---|---|---|
| Price | $18.76 | $24.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $19.28 | ★ $48.09 |
| AVG Volume (30 Days) | 2.2M | ★ 2.2M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,019,965,000.00 | $55,701,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $12.76 | $19.01 |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | ★ 147.22 | N/A |
| 52 Week Low | $11.52 | $13.53 |
| 52 Week High | $18.83 | $35.25 |
| Indicator | BANC | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 68.44 | 52.36 |
| Support Level | $18.37 | $20.23 |
| Resistance Level | $18.71 | $25.56 |
| Average True Range (ATR) | 0.51 | 1.61 |
| MACD | 0.19 | 0.41 |
| Stochastic Oscillator | 99.45 | 72.11 |
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.